Caricamento...

SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice

Persons with type 1 and type 2 diabetes have increased fracture risk, attributed to deficits in the microarchitecture and strength of diabetic bone, thought to be mediated, in part, by the consequences of chronic hyperglycemia. Therefore, to examine the effects of a glucose-lowering SGLT2 inhibitor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Bone
Autori principali: Thrailkill, Kathryn M., Bunn, R. Clay, Nyman, Jeffry S., Rettiganti, Mallikarjuna R., Cockrell, Gael E., Wahl, Elizabeth C., Uppuganti, Sasidhar, Lumpkin, Charles K., Fowlkes, John L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4679447/
https://ncbi.nlm.nih.gov/pubmed/26211996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2015.07.025
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !